Prestige Consumer Healthcare

PBH

Market cap $3.04B

TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Barclays 18th Annual Global Consumer Staples Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Ron Lombardi - Chairman, President & CEO Christine Sacco - CFO & COO Presentation Ron Lombardi Chairman, President & CEO Okay. Good afternoon, everyone.

TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the “Investors” section and the “Events and Presentations” tab, or by using the following link:

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q1 2026 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Christine Sacco - CFO & COO Philip David Terpolilli - Director of Investor Relations Ronald M. Lombardi - Chairman, President & CEO Conference Call Participants Anthony Chester Lebiedzinski - Sidoti & Company, LLC Douglas Matthai Lane - Water Tower Research LLC Glenn West - William Blair & Company L.L.C.

Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago.

Prestige Consumer Healthcare (PBH 1.51%), the over-the-counter (OTC) healthcare product company behind brands such as Clear Eyes, Monistat, and Chloraseptic, released its first-quarter results for fiscal 2026 on August 7, 2025. The most vital news was that GAAP revenue and earnings per share both fell short of expectations, mainly due to supply constraints in its North American Eye & Ear Care business and some orders that were accelerated into Q4 FY2025.

Revenue of $249.5 million in Q1; decline driven by limited eye care supply Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90 Announces agreement to acquire current eye care supplier Pillar5 Pharma Revising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025.

Beyond analysts' top-and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.